Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. increased its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 202.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 16,710 shares of the financial services provider’s stock after acquiring an additional 11,190 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P.’s holdings in iShares NASDAQ Biotechnology Index were worth $1,784,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of iShares NASDAQ Biotechnology Index by 200.0% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,907,625 shares of the financial services provider’s stock valued at $203,677,000 after buying an additional 1,271,750 shares during the period. CHURCHILL MANAGEMENT Corp boosted its stake in shares of iShares NASDAQ Biotechnology Index by 223.2% during the 4th quarter. CHURCHILL MANAGEMENT Corp now owns 1,801,330 shares of the financial services provider’s stock valued at $192,328,000 after buying an additional 1,244,066 shares during the period. Commerce Bank boosted its stake in shares of iShares NASDAQ Biotechnology Index by 217.0% during the 4th quarter. Commerce Bank now owns 793,250 shares of the financial services provider’s stock valued at $84,695,000 after buying an additional 543,005 shares during the period. Alliancebernstein L.P. boosted its stake in shares of iShares NASDAQ Biotechnology Index by 79.6% during the 4th quarter. Alliancebernstein L.P. now owns 1,140,301 shares of the financial services provider’s stock valued at $121,750,000 after buying an additional 505,243 shares during the period. Finally, Two Sigma Advisers LP boosted its stake in shares of iShares NASDAQ Biotechnology Index by 5,101.7% during the 4th quarter. Two Sigma Advisers LP now owns 312,099 shares of the financial services provider’s stock valued at $33,323,000 after buying an additional 306,099 shares during the period. 61.47% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of iShares NASDAQ Biotechnology Index (IBB) opened at $113.92 on Wednesday. iShares NASDAQ Biotechnology Index has a 52 week low of $94.20 and a 52 week high of $119.30.

WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/03/14/ishares-nasdaq-biotechnology-index-ibb-position-boosted-by-holt-capital-advisors-l-l-c-dba-holt-capital-partners-l-p.html.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.